Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.55 |
| ▸ | SLC18A3 | Q16572 | 7/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6471905 | 1.00 | OPRL1 (0.55) | OPRL1OPRM1KCNH2SLC18A3SIGMAR1 | |
| SCHEMBL6471651 | 0.89 | OPRL1 (0.48) | OPRL1OPRM1KCNH2SLC18A3SIGMAR1 | |
| SCHEMBL6471648 | 0.89 | OPRL1 (0.48) | OPRL1OPRM1KCNH2SLC18A3SIGMAR1 | |
| SCHEMBL6504054 | 0.89 | OPRL1 (0.70) | OPRL1OPRM1KCNH2SLC18A3SIGMAR1 | |
| SCHEMBL6501770 | 0.89 | OPRL1 (0.70) | OPRL1OPRM1KCNH2SLC18A3SIGMAR1 | |
| SCHEMBL6472981 | 0.83 | OPRM1 (0.79) | OPRL1OPRM1KCNH2SIGMAR1 | |
| SCHEMBL6501857 | 0.83 | OPRL1 (0.52) | OPRL1OPRM1KCNH2 | |
| SCHEMBL6501020 | 0.80 | OPRL1 (0.59) | OPRL1OPRM1KCNH2SLC18A3SIGMAR1 | |
| SCHEMBL6501015 | 0.80 | OPRL1 (0.59) | OPRL1OPRM1KCNH2SLC18A3SIGMAR1 | |
| SCHEMBL6506055 | 0.77 | OPRL1 (0.61) | OPRL1OPRM1KCNH2SLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192339-A1 | Compounds | BIOVITRUM AB (SE) | 2005-09-01 | — | — | US | disclosed |
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | disclosed |
| WO-2005016913-A1 | TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS | PFIZER JAPAN, INC. (JP) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | OPRL1, NR1H3, HRH3 | OPRL1 1/4885OPRM1 8/4885KCNH2 378/4885 |
| US-20050192339-A1 | Compounds | MCHR1, HCRTR1, NPY1R | OPRL1 22/4885OPRM1 38/4885KCNH2 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.